University of Groningen

CRISPR/Cas9 and targeted cancer therapy

Liu, Bin

DOI:
[10.33612/diss.99103461](https://doi.org/10.33612/diss.99103461)

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version
Publisher's PDF, also known as Version of record

Publication date:
2019

[Link to publication in University of Groningen/UMCG research database](#)

Citation for published version (APA):
Liu, B. (2019). *CRISPR/Cas9 and targeted cancer therapy*. [Thesis fully internal (DIV), University of Groningen]. University of Groningen. <https://doi.org/10.33612/diss.99103461>

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: <https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment>.

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

CRISPR/Cas9 and targeted cancer therapy

Bin Liu

The research described in this thesis was carried out at the department of Chemical and Pharmaceutical Biology at the University of Groningen.

The research was carried out according to the requirements of the Graduate School of Science, Faculty of Science and Engineering, University of Groningen, The Netherlands

Printing of this thesis was financially supported by the University Library and the Graduate School of Science, University of Groningen, The Netherlands.

Printing: Ridderprint BV | www.ridderprint.nl

ISBN (ebook): 978-94-6375-611-2

ISBN (printed version): 978-94-6375-610-5

Copyright © 2019 Bin Liu. All rights are reserved. No part of this thesis may be reproduced or transmitted in any form or by any means without the prior permission in writing of the author.

university of
 groningen

CRISPR/Cas9 and targeted cancer therapy

PhD thesis

to obtain the degree of PhD at the
University of Groningen
on the authority of the
Rector Magnificus Prof. C. Wijmenga
and in accordance with
the decision by the College of Deans.

This thesis will be defended in public on

Tuesday 29 October 2019 at 11.00 hours

by

Bin Liu

born on 16 February 1989
in Jiangsu, China

Supervisors

Prof. H.J. Haisma

Prof. F.J. Dekker

Assessment Committee

Prof. M. Schmidt

Prof. V.W. van Beusechem

Prof. F. Foijer

Contents

Chapter 1	Scope and outline of this thesis	7
Chapter 2	CRISPR/Cas9: A powerful tool for identification of new targets for cancer treatment	17
Chapter 3	CRISPR/Cas9 for overcoming drug resistance in solid tumors	75
Chapter 4	Transcriptional activation of cyclin D1 via HER2/HER3 contributes to cell survival and tyrosine kinase inhibitor resistance in non-small cell lung carcinoma	101
Chapter 5	CX Chemokine Receptor 7 Contributes to Survival of KRAS-Mutant Non-Small Cell Lung Cancer upon Loss of Epidermal Growth Factor Receptor	135
Chapter 6	CRISPR-mediated ablation of overexpressed EGFR in combination with sunitinib significantly suppresses renal cell carcinoma proliferation	171
Chapter 7	Inhibition of Histone deacetylase 1 (HDAC1) and HDAC2 enhances CRISPR/Cas9 genome editing	195
Chapter 8	Summary and Future Perspectives	236
Appendices	Acknowledgement	
	List of publication	
	About the author	